Despite the progress recently, the withdrawal of the FAAH inhibitor during clinical trial and anti-obesity CB1R antagonist due adverse effects engenders cautionary approaches in clinical trials. This evidence concerns the gene FAAH and obesity due to melanocortin 4 receptor deficiency.